Clinical Outcomes of Tenofovir, Lamivudine, and Dolutegravir in Treatment-Naïve versus Treatment-Experienced HIV Patients: A Single-Center Retrospective Cohort Study in Indonesia

BACKGROUND: The World Health Organization recommended dolutegravir (DTG)-based antiretroviral therapy (ART) as first- and second-line treatment for people living with HIV (PLHIV) in 2018. Given its widespread use across diverse patient populations, ongoing evaluation of the real-world effectiveness and tolerability of DTG-based ART particularly across treatment-naïve (TN) and treatment-experienced (TE) patients remains essential to inform routine clinical practice. MATERIALS AND METHODS: tests for comparison of continuous weight change, which was summarized as median. RESULTS: =0.010). CONCLUSION: After 12 months of TLD therapy, no significant differences were observed between TN and TE HIV patients in virological response, immunological status, or toxicity/adverse events. A significant difference was observed in weight change, with greater weight gain among TN patients.